anti-TL1A/IL-23 antibody

An anti-TL1A/IL-23 antibody is a bispecific monoclonal antibody designed to simultaneously target and neutralize tumor necrosis factor-like ligand 1A (TL1A) and interleukin-23 (IL-23). This dual-targeting approach is primarily developed for the treatment of inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, as well as other immune-mediated inflammatory diseases. TL1A signaling through its receptor DR3 promotes Th1 and Th17 cell differentiation and drives tissue fibrosis, while IL-23 is a key cytokine that sustains pathogenic Th17 cell populations and drives chronic mucosal inflammation. By blocking both pathways, these bispecific antibodies aim to achieve synergistic anti-inflammatory and anti-fibrotic efficacy, potentially overcoming the therapeutic efficacy ceiling of single-target biologics. Several candidates, such as Boan Biotech's BA2201, InnoCare's ICP-B161, Simcere's SIM0709, and Mirador Therapeutics' MT-251, are in preclinical or early clinical development.